Neurogene Inc. (NGNE)
NASDAQ: NGNE · Real-Time Price · USD
24.01
-0.09 (-0.37%)
Dec 27, 2024, 10:04 AM EST - Market open

Neurogene Statistics

Total Valuation

Neurogene has a market cap or net worth of $356.03 million. The enterprise value is $231.50 million.

Market Cap 356.03M
Enterprise Value 231.50M

Important Dates

The last earnings date was Monday, November 18, 2024, after market close.

Earnings Date Nov 18, 2024
Ex-Dividend Date n/a

Share Statistics

Neurogene has 14.83 million shares outstanding. The number of shares has increased by 116.71% in one year.

Current Share Class 14.83M
Shares Outstanding 14.83M
Shares Change (YoY) +116.71%
Shares Change (QoQ) +0.07%
Owned by Insiders (%) 11.61%
Owned by Institutions (%) 51.19%
Float 5.26M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio n/a
Forward PS n/a
PB Ratio 2.28
P/TBV Ratio 2.60
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 250.27
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 9.09, with a Debt / Equity ratio of 0.10.

Current Ratio 9.09
Quick Ratio 8.84
Debt / Equity 0.10
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -5,825.08

Financial Efficiency

Return on equity (ROE) is -53.63% and return on invested capital (ROIC) is -43.84%.

Return on Equity (ROE) -53.63%
Return on Assets (ROA) -39.75%
Return on Capital (ROIC) -43.84%
Revenue Per Employee $10,165
Profits Per Employee -$36,000
Employee Count 91
Asset Turnover 0.01
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +51.87% in the last 52 weeks.

Beta (5Y) n/a
52-Week Price Change +51.87%
50-Day Moving Average 35.30
200-Day Moving Average 37.69
Relative Strength Index (RSI) 44.05
Average Volume (20 Days) 295,877

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, Neurogene had revenue of $925,000 and -$3.28 million in losses. Loss per share was -$0.26.

Revenue 925,000
Gross Profit -56.73M
Operating Income -75.73M
Pretax Income -55.44M
Net Income -3.28M
EBITDA -72.45M
EBIT -75.73M
Loss Per Share -$0.26
Full Income Statement

Balance Sheet

The company has $138.99 million in cash and $13.12 million in debt, giving a net cash position of $125.87 million or $8.49 per share.

Cash & Cash Equivalents 138.99M
Total Debt 13.12M
Net Cash 125.87M
Net Cash Per Share $8.49
Equity (Book Value) 137.41M
Book Value Per Share 10.56
Working Capital 127.85M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$70.08 million and capital expenditures -$820,000, giving a free cash flow of -$70.90 million.

Operating Cash Flow -70.08M
Capital Expenditures -820,000
Free Cash Flow -70.90M
FCF Per Share -$4.78
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin -8,186.59%
Pretax Margin -5,756.43%
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

Neurogene does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -116.71%
Shareholder Yield -116.71%
Earnings Yield -0.92%
FCF Yield -19.84%

Analyst Forecast

The average price target for Neurogene is $60.80, which is 153.23% higher than the current price. The consensus rating is "Strong Buy".

Price Target $60.80
Price Target Difference 153.23%
Analyst Consensus Strong Buy
Analyst Count 6
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Neurogene has an Altman Z-Score of 7.52 and a Piotroski F-Score of 1.

Altman Z-Score 7.52
Piotroski F-Score 1